Post-earnings recap
Reported
Mon, Feb 28, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a loss per share that was slightly worse than expected, contributing to a minor decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term prospects. The stock's reaction reflects uncertainty in the market regarding the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.43 | N/A | -2.38% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook without offering specific guidance. They emphasized ongoing efforts in their development pipeline.
Management did not provide specific guidance for future quarters.
The focus remains on advancing pipeline projects.